The treatment outcome of patients with advanced non-small cell lung cancer (NSCLC) with anaplastic lymphoma kinase (ALK) chromosomal rearrangements, a distinct subset of lung cancer, has been improved by the development of tyrosine kinase inhibitors (TKIs)1. This evidence concerns the gene ALK and non-small cell lung carcinoma.